{"cdcTestId":"2021-0033","testcaseName":"Patient is 7 years old and was administered two dose of Pfizer Covid-19 vaccine (CVX 208). Forecast booster dose.","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test Type","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"2015-09-28T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-12-14T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2021-08-22T20:00:00","dateUpdated":"2022-10-19T12:13:32.601","generalDescription":"This test case describes when a child that is less than 12 years old and was administered a first and a second dose of the Pfizer Covid-19 vaccine (CVX 208),  that the doses are considered valid. Another dose should be forecast.","changedInVersion":"4.28","reasonForChange":"v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.\nv4.23 Updated the test case based on new updated ACIP Guideline Recommendations (05/19/22) that expands the eligibility for a booster dose for children ages 5-11 years, 5 months after the second dose.\nv4.15 Updated the Forecast Dose Number field to blank."}